To investigate the role of KLF4 in Chemotherapeutic insensitivity of prostate cancer, we first analysed the expression level of KLF4 under cisplatin (CDDP) treatment and found that KLF4 expression was increased in response to cisplatin (Fig. 1a). The gene discussed is KLF4; the disease is prostate carcinoma.